查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1865445

醫療保健IPO市場預測至2032年：按營業單位類型、IPO規模和結構、投資者類型、上市市場、治療領域和地區分類的全球分析

Healthcare IPOs Market Forecasts to 2032 - Global Analysis By Entity Type, IPO Size & Structure, Investor Type, Listing Venue, Therapeutic Area and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計 2025 年全球醫療保健 IPO 市場規模將達到 18 億美元，到 2032 年將達到 28 億美元，預測期內複合年成長率為 6.3%。

醫療保健IPO是指醫療保健產業公司（包括製藥、生技、醫療設備、診斷和數位醫療）的首次公開發行（IPO）。這些IPO使私人醫療保健公司能夠首次向公眾發行股票，以籌集資金用於擴張、研發和創新。醫療保健IPO通常受醫療技術創新、監管核准以及投資者對生命科學領域的興趣所驅動，而生命科學領域在為高成長企業提供資金和擴大公眾獲得最先進治療的機會方面發揮著關鍵作用。市場趨勢可能受到臨床試驗結果、政策變化和更廣泛的經濟狀況的影響。

醫療保健技術的快速創新

醫療保健技術的快速創新是推動醫療保健IPO市場發展的關鍵因素。生物技術、數位醫療、人工智慧驅動的診斷以及穿戴式醫療設備等領域的突破性進展正在改變患者照護，並創造成長機會。這些進步吸引了投資人的關注，並加速了企業上市進程。Start-Ups和成熟公司都在探索IPO，以資金籌措、擴大營運規模並將創新療法商業化。隨著醫療保健技術的不斷發展，它正在推動充滿活力的IPO市場，從而支持創新並擴大尖端醫療保健解決方案的覆蓋範圍。

更嚴格的IPO標準

更嚴格的IPO標準是阻礙因素要求，以確保透明度、財務穩定性和投資者保護。這些要求包括嚴格的財務資訊揭露、臨床試驗檢驗和管治標準。雖然這些措施有助於維護市場誠信，但也可能導致IPO計劃延遲甚至終止，尤其對於早期醫療保健公司。克服這些障礙需要完善的合規策略和投資者關係準備，這可能會使一些公司難以有效率地進入公開資本市場。

數位醫療的擴展

數位醫療的蓬勃發展為醫療健康領域的IPO市場帶來了巨大的機會。遠端醫療、遠端監測、人工智慧診斷和健康數據平台正在重塑醫療服務模式。在對便利、科技驅動型醫療服務日益成長的需求驅動下，數位醫療Start-Ups正在籌集大量創業投資，並積極籌備上市。 IPO能夠為這些企業提供必要的資金，以擴大平台規模、加強網路安全並拓展全球業務。這場數位轉型正在催生新的收入來源，並將醫療健康領域的IPO打造成為通往下一代醫療創新的入口。

監理複雜性

監管的複雜性對醫療保健IPO市場構成重大威脅。尋求上市的公司面臨著應對不同司法管轄區內多樣化且不斷變化的醫療保健法規的挑戰。遵守臨床試驗通訊協定、資料隱私法和財務報告準則進一步增加了風險和成本。監管核准的延遲和政策變化會影響公司估值和投資者信心。為了應對這些挑戰，公司必須投資法律專業知識、透明的管治和適應性策略，以滿足全球監管要求。

新冠疫情的影響：

新冠疫情對醫療保健IPO市場產生了複雜的影響。疫情一方面擾亂了臨床試驗，延緩了法規核准，另一方面也凸顯了醫療創新的重要性。疫苗、診斷和數位醫療解決方案的研發企業獲得了投資者的更多關注，IPO進程也隨之加快。此次危機也凸顯了敏捷、以科學為主導的企業的價值，推動了醫療保健相關企業數量的激增。疫情過後，市場持續受益於更強的市場韌性以及公共和私人對技術進步的更多投資。

預計在預測期內，生技公司板塊將佔據最大的市場佔有率。

預計在預測期內，生技公司將佔據最大的市場佔有率。生物技術公司處於醫療創新前沿，致力於開發癌症、罕見疾病和慢性病的治療方法。其高成長潛力和頻繁的突破性進展吸引了投資者的濃厚興趣。首次公開發行（IPO）是臨床試驗、監管核准和商業化的重要資金來源。隨著個人化醫療和基因療法日益受到關注，生物技術公司主導IPO市場，推動資本流入和醫療保健領域的變革性進步。

預計在預測期內，循環系統領域將實現最高的複合年成長率。

預計在預測期內，循環系統領域將呈現最高的成長率，這主要得益於循環系統疾病盛行率的上升、人口老化以及對先進診斷和治療方法需求的不斷成長。開發創新心臟設備、數位監測工具和微創療法的公司正吸引投資者的目光。首次公開募股（IPO）將使這些公司能夠擴大研發規模、提升生產能力並進入新市場。鑑於心臟健康仍然是全球關注的焦點，心臟病學領域的快速技術創新和臨床相關性有望推動IPO活動的加速和持續成長。

佔比最大的地區：

預計亞太地區將在預測期內保持最大的市場佔有率，這主要得益於該地區不斷擴大的醫療基礎設施、日益​​壯大的中產階級以及政府對生物技術創新的支持，這些因素將推動市場成長。中國、印度和韓國等國家已培育出充滿活力的Start-Ups生態系統，並為企業提供了便利的資本市場進入管道。當地交易所正吸引許多醫療健康相關企業上市，而全球投資者也積極尋求在亞洲蓬勃發展的醫療健康領域投資的機會。這一發展勢頭將使亞太地區在醫療健康IPO領域佔據主導地位。

複合年成長率最高的地區：

預計北美在預測期內將呈現最高的複合年成長率。這主要得益於該地區強大的生命科學生態系統、活躍的創業投資投資以及有利的法規環境，這些因素共同支持了IPO的快速成長。總部位於美國的生物技術和醫療技術公司在創新方面處於領先地位，並經常透過IPO為臨床試驗和商業化資金籌措。數位醫療和個人化醫療的興起進一步推動了上市進程。憑藉成熟的資本市場和投資者對醫療保健創新的濃厚興趣，北美仍然是高成長醫療保健IPO的熱點地區。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 主要參與者（最多3家公司）的SWOT分析
  • 區域細分
    • 根據客戶要求，對主要國家的市場規模進行估算和預測，併計算複合年成長率（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要參與者的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球醫療保健 IPO 市場（以營業單位類型分類）

  • 製藥公司
  • 生技公司
  • 醫療設備製造商
  • 診斷和實驗室服務
  • 醫療保健服務和提供者
  • 數位健康和​​醫療保健資訊技術

6. 全球醫療保健IPO市場：按IPO規模和結構分類

  • 小型股IPO
  • 中型IPO
  • 大型IPO
  • SPAC合併和反向收購

7. 全球醫療保健IPO市場（依投資者類型分類）

  • 機構投資者
  • 個人投資者
  • 創業投資與私募股權
  • 策略企業投資者

第8章：全球醫療保健IPO市場（依上市市場分類）

  • 主要交易所
  • 區域交易所
  • 交叉上市和美國存託憑證

9. 全球醫療保健IPO市場（依治療領域分類）

  • 腫瘤學
  • 心臟病學
  • 罕見疾病和孤兒藥
  • 基因和細胞療法
  • 數位療法和人工智慧診斷

10. 全球醫療保健IPO市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Galderma SA
  • BrightSpring Health Services
  • Concentra Group Holdings
  • PACS Group Inc.
  • CG Oncology Inc.
  • Tempus AI Inc.
  • Auna SA
  • Emcure Pharmaceuticals Ltd.
  • Sai Life Sciences Ltd.
  • Sagility India Ltd.
  • Hinge Health
  • Omada Health
  • Kyverna Therapeutics Inc.
  • Bicara Therapeutics Inc.
  • Ardent Health Partners Inc.
Product Code: SMRC32126

According to Stratistics MRC, the Global Healthcare IPOs Market is accounted for $1.8 billion in 2025 and is expected to reach $2.8 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Healthcare IPOs refer to the initial public offerings of companies operating within the healthcare sector, including pharmaceuticals, biotechnology, medical devices, diagnostics, and digital health. These IPOs allow private healthcare firms to raise capital by offering shares to the public for the first time, enabling expansion, research, and innovation. Healthcare IPOs are often driven by breakthroughs in medical technology, regulatory approvals, and investor interest in life sciences. They play a crucial role in funding high-growth ventures and advancing public access to cutting-edge treatments. Market performance can be influenced by clinical trial results, policy changes, and broader economic conditions.

Market Dynamics:

Driver:

Rapid innovation in health tech

Rapid innovation in health technology is a key driver of the Healthcare IPOs Market. Breakthroughs in biotechnology, digital health, AI-driven diagnostics, and wearable medical devices are transforming patient care and creating high-growth opportunities. These advancements attract investor interest and accelerate the path to public offerings. Startups and established firms alike seek IPOs to fund R&D, scale operations, and commercialize novel treatments. As health tech continues to evolve, it fuels a dynamic IPO landscape that supports innovation and expands access to cutting-edge healthcare solutions.

Restraint:

Stricter IPO criteria

Stricter IPO criteria present a significant restraint to the Healthcare IPOs Market. Regulatory bodies and stock exchanges have tightened listing requirements to ensure transparency, financial stability, and investor protection. These include rigorous financial disclosures, clinical trial validations, and governance standards. While these measures enhance market integrity, they can delay or deter IPO plans, especially for early-stage healthcare firms. Navigating these hurdles requires robust compliance strategies and investor readiness, making it challenging for some companies to access public capital markets efficiently.

Opportunity:

Digital healthcare expansion

The expansion of digital healthcare presents a major opportunity for the Healthcare IPOs Market. Telemedicine, remote monitoring, AI-powered diagnostics, and health data platforms are reshaping care delivery. As demand for accessible, tech-enabled healthcare grows, digital health startups are attracting significant venture capital and preparing for public listings. IPOs provide the funding needed to scale platforms, enhance cybersecurity, and expand global reach. This digital transformation is unlocking new revenue streams and positioning healthcare IPOs as a gateway to next-generation medical innovation.

Threat:

Regulatory complexity

Regulatory complexity poses a notable threat to the Healthcare IPOs Market. Navigating diverse and evolving healthcare regulations across jurisdictions can be daunting for companies seeking to go public. Compliance with clinical trial protocols, data privacy laws, and financial reporting standards adds layers of risk and cost. Delays in regulatory approvals or policy shifts can impact valuation and investor confidence. To mitigate these challenges, firms must invest in legal expertise, transparent governance, and adaptive strategies to align with global regulatory expectations.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the Healthcare IPOs Market. While it disrupted clinical trials and delayed regulatory reviews, it also spotlighted the importance of healthcare innovation. Companies developing vaccines, diagnostics, and digital health solutions experienced heightened investor interest and accelerated IPO timelines. The crisis underscored the value of agile, science-driven firms, leading to a surge in healthcare listings. Post-pandemic, the market continues to benefit from increased public and private investment in health resilience and technological advancement.

The biotechnology firms segment is expected to be the largest during the forecast period

The biotechnology firms segment is expected to account for the largest market share during the forecast period, as biotech companies are at the forefront of medical innovation, developing therapies for cancer, rare diseases, and chronic conditions. Their high growth potential and frequent breakthroughs attract strong investor interest. IPOs provide critical funding for clinical trials, regulatory approvals, and commercialization. As personalized medicine and gene therapies gain traction, biotech firms dominate the IPO landscape, driving both capital inflow and transformative healthcare advancements.

The cardiology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cardiology segment is predicted to witness the highest growth rate, due to rising prevalence of cardiovascular diseases, aging populations, and demand for advanced diagnostics and treatments fuel growth. Companies developing innovative cardiac devices, digital monitoring tools, and minimally invasive procedures are gaining investor attention. IPOs enable these firms to expand R&D, scale production, and enter new markets. As heart health remains a global priority, the cardiology segment's rapid innovation and clinical relevance position it for accelerated IPO activity and sustained growth.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to region's expanding healthcare infrastructure, rising middle-class population, and government support for biotech innovation drive market growth. Countries like China, India, and South Korea are fostering vibrant startup ecosystems and easing access to capital markets. Local exchanges are attracting healthcare listings, while global investors seek exposure to Asia's dynamic health sector. This momentum positions Asia Pacific as a dominant force in healthcare IPO activity.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to region's robust life sciences ecosystem, strong venture capital presence, and favorable regulatory environment support rapid IPO growth. U.S.-based biotech and medtech firms lead in innovation, frequently leveraging IPOs to fund clinical trials and commercialization. The rise of digital health and personalized medicine further fuels listings. With mature capital markets and investor appetite for healthcare innovation, North America remains a hotspot for high-growth healthcare IPOs.

Key players in the market

Some of the key players in Healthcare IPOs Market include Galderma S.A., BrightSpring Health Services, Concentra Group Holdings, PACS Group Inc., CG Oncology Inc., Tempus AI Inc., Auna S.A., Emcure Pharmaceuticals Ltd., Sai Life Sciences Ltd., Sagility India Ltd., Hinge Health, Omada Health, Kyverna Therapeutics Inc., Bicara Therapeutics Inc., Ardent Health Partners Inc.

Key Developments:

In January 2025, Syensqo and Ardent Process Technologies have formalised a strategic partnership to accelerate point-source carbon capture and olefin-paraffin separation technologies, combining Syensqo's materials science prowess and industrial scale with Ardent's high-performance membrane solutions.

In October 2024, L'Oreal Groupe has acquired a 10 % stake in Galderma Group AG and entered a strategic scientific partnership, combining Galderma's dermatology-solutions expertise with L'Oreal's strengths in skin-biology, diagnostic tools and evaluation methods to accelerate innovation in the aesthetics and dermatology space.

Entity Types Covered:

  • Pharmaceutical Companies
  • Biotechnology Firms
  • Medical Device Manufacturers
  • Diagnostics & Laboratory Services
  • Healthcare Services & Providers
  • Digital Health & Health IT

IPO Sizes & Structures Covered:

  • Small-cap IPOs
  • Mid-cap IPOs
  • Large-cap IPOs
  • SPAC Mergers & Reverse Mergers

Investor Types Covered:

  • Institutional Investors
  • Retail Investors
  • Venture Capital & Private Equity
  • Strategic Corporate Investors

Listing Venues Covered:

  • Major Exchanges
  • Regional Exchanges
  • Cross-Listings & ADRs

Therapeutic Areas Covered:

  • Oncology
  • Cardiology
  • Rare Diseases & Orphan Drugs
  • Gene & Cell Therapies
  • Digital Therapeutics & AI Diagnostics

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Healthcare IPOs Market, By Entity Type

  • 5.1 Introduction
  • 5.2 Pharmaceutical Companies
  • 5.3 Biotechnology Firms
  • 5.4 Medical Device Manufacturers
  • 5.5 Diagnostics & Laboratory Services
  • 5.6 Healthcare Services & Providers
  • 5.7 Digital Health & Health IT

6 Global Healthcare IPOs Market, By IPO Size & Structure

  • 6.1 Introduction
  • 6.2 Small-cap IPOs
  • 6.3 Mid-cap IPOs
  • 6.4 Large-cap IPOs
  • 6.5 SPAC Mergers & Reverse Mergers

7 Global Healthcare IPOs Market, By Investor Type

  • 7.1 Introduction
  • 7.2 Institutional Investors
  • 7.3 Retail Investors
  • 7.4 Venture Capital & Private Equity
  • 7.5 Strategic Corporate Investors

8 Global Healthcare IPOs Market, By Listing Venue

  • 8.1 Introduction
  • 8.2 Major Exchanges
  • 8.3 Regional Exchanges
  • 8.4 Cross-Listings & ADRs

9 Global Healthcare IPOs Market, By Therapeutic Area

  • 9.1 Introduction
  • 9.2 Oncology
  • 9.3 Cardiology
  • 9.4 Rare Diseases & Orphan Drugs
  • 9.5 Gene & Cell Therapies
  • 9.6 Digital Therapeutics & AI Diagnostics

10 Global Healthcare IPOs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Galderma S.A.
  • 12.2 BrightSpring Health Services
  • 12.3 Concentra Group Holdings
  • 12.4 PACS Group Inc.
  • 12.5 CG Oncology Inc.
  • 12.6 Tempus AI Inc.
  • 12.7 Auna S.A.
  • 12.8 Emcure Pharmaceuticals Ltd.
  • 12.9 Sai Life Sciences Ltd.
  • 12.10 Sagility India Ltd.
  • 12.11 Hinge Health
  • 12.12 Omada Health
  • 12.13 Kyverna Therapeutics Inc.
  • 12.14 Bicara Therapeutics Inc.
  • 12.15 Ardent Health Partners Inc.

List of Tables

  • Table 1 Global Healthcare IPOs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Healthcare IPOs Market Outlook, By Entity Type (2024-2032) ($MN)
  • Table 3 Global Healthcare IPOs Market Outlook, By Pharmaceutical Companies (2024-2032) ($MN)
  • Table 4 Global Healthcare IPOs Market Outlook, By Biotechnology Firms (2024-2032) ($MN)
  • Table 5 Global Healthcare IPOs Market Outlook, By Medical Device Manufacturers (2024-2032) ($MN)
  • Table 6 Global Healthcare IPOs Market Outlook, By Diagnostics & Laboratory Services (2024-2032) ($MN)
  • Table 7 Global Healthcare IPOs Market Outlook, By Healthcare Services & Providers (2024-2032) ($MN)
  • Table 8 Global Healthcare IPOs Market Outlook, By Digital Health & Health IT (2024-2032) ($MN)
  • Table 9 Global Healthcare IPOs Market Outlook, By IPO Size & Structure (2024-2032) ($MN)
  • Table 10 Global Healthcare IPOs Market Outlook, By Small-cap IPOs (2024-2032) ($MN)
  • Table 11 Global Healthcare IPOs Market Outlook, By Mid-cap IPOs (2024-2032) ($MN)
  • Table 12 Global Healthcare IPOs Market Outlook, By Large-cap IPOs (2024-2032) ($MN)
  • Table 13 Global Healthcare IPOs Market Outlook, By SPAC Mergers & Reverse Mergers (2024-2032) ($MN)
  • Table 14 Global Healthcare IPOs Market Outlook, By Investor Type (2024-2032) ($MN)
  • Table 15 Global Healthcare IPOs Market Outlook, By Institutional Investors (2024-2032) ($MN)
  • Table 16 Global Healthcare IPOs Market Outlook, By Retail Investors (2024-2032) ($MN)
  • Table 17 Global Healthcare IPOs Market Outlook, By Venture Capital & Private Equity (2024-2032) ($MN)
  • Table 18 Global Healthcare IPOs Market Outlook, By Strategic Corporate Investors (2024-2032) ($MN)
  • Table 19 Global Healthcare IPOs Market Outlook, By Listing Venue (2024-2032) ($MN)
  • Table 20 Global Healthcare IPOs Market Outlook, By Major Exchanges (2024-2032) ($MN)
  • Table 21 Global Healthcare IPOs Market Outlook, By Regional Exchanges (2024-2032) ($MN)
  • Table 22 Global Healthcare IPOs Market Outlook, By Cross-Listings & ADRs (2024-2032) ($MN)
  • Table 23 Global Healthcare IPOs Market Outlook, By Therapeutic Area (2024-2032) ($MN)
  • Table 24 Global Healthcare IPOs Market Outlook, By Oncology (2024-2032) ($MN)
  • Table 25 Global Healthcare IPOs Market Outlook, By Cardiology (2024-2032) ($MN)
  • Table 26 Global Healthcare IPOs Market Outlook, By Rare Diseases & Orphan Drugs (2024-2032) ($MN)
  • Table 27 Global Healthcare IPOs Market Outlook, By Gene & Cell Therapies (2024-2032) ($MN)
  • Table 28 Global Healthcare IPOs Market Outlook, By Digital Therapeutics & AI Diagnostics (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.